Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.

Gene therapy has been proposed for a wide range of human diseases but few have received the level of attention over such a prolonged period as cystic fibrosis (CF) with over 20 clinical studies undertaken. Following a 10-year interval, clinical trials of an aerosolisable non-viral gene transfer agen...

Full description

Bibliographic Details
Main Authors: Pringle, I, Hyde, S, Gill, DR
Format: Journal article
Language:English
Published: 2009
_version_ 1826259211736055808
author Pringle, I
Hyde, S
Gill, DR
author_facet Pringle, I
Hyde, S
Gill, DR
author_sort Pringle, I
collection OXFORD
description Gene therapy has been proposed for a wide range of human diseases but few have received the level of attention over such a prolonged period as cystic fibrosis (CF) with over 20 clinical studies undertaken. Following a 10-year interval, clinical trials of an aerosolisable non-viral gene transfer agent have recently been initiated by researchers in the United Kingdom. Here we review the rationale and requirements for effective gene therapy for CF lung disease. The previous non-viral gene therapy trials are discussed and the prospects for the current leading non-viral formulations for CF gene therapy are considered. Factors affecting the selection and design of the plasmid DNA molecule, likely to be of central importance to clinical efficacy, are reviewed and we describe the potential merits of the formulation that has been selected for the forthcoming UK trials.
first_indexed 2024-03-06T18:46:18Z
format Journal article
id oxford-uuid:0ea41eb3-8bcd-47cb-beaf-5a3809b526a5
institution University of Oxford
language English
last_indexed 2024-03-06T18:46:18Z
publishDate 2009
record_format dspace
spelling oxford-uuid:0ea41eb3-8bcd-47cb-beaf-5a3809b526a52022-03-26T09:46:59ZNon-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0ea41eb3-8bcd-47cb-beaf-5a3809b526a5EnglishSymplectic Elements at Oxford2009Pringle, IHyde, SGill, DRGene therapy has been proposed for a wide range of human diseases but few have received the level of attention over such a prolonged period as cystic fibrosis (CF) with over 20 clinical studies undertaken. Following a 10-year interval, clinical trials of an aerosolisable non-viral gene transfer agent have recently been initiated by researchers in the United Kingdom. Here we review the rationale and requirements for effective gene therapy for CF lung disease. The previous non-viral gene therapy trials are discussed and the prospects for the current leading non-viral formulations for CF gene therapy are considered. Factors affecting the selection and design of the plasmid DNA molecule, likely to be of central importance to clinical efficacy, are reviewed and we describe the potential merits of the formulation that has been selected for the forthcoming UK trials.
spellingShingle Pringle, I
Hyde, S
Gill, DR
Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.
title Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.
title_full Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.
title_fullStr Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.
title_full_unstemmed Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.
title_short Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.
title_sort non viral vectors in cystic fibrosis gene therapy recent developments and future prospects
work_keys_str_mv AT pringlei nonviralvectorsincysticfibrosisgenetherapyrecentdevelopmentsandfutureprospects
AT hydes nonviralvectorsincysticfibrosisgenetherapyrecentdevelopmentsandfutureprospects
AT gilldr nonviralvectorsincysticfibrosisgenetherapyrecentdevelopmentsandfutureprospects